BMRA News and Press, Biomerica Inc.

Fiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025 Full-year net loss improved by approximately 24% to approximately $3.8 million InFoods IBS update: 100% of all initial valid claims processed to date have been paid at the full...

Financing priced at $1.60 with no warrants or discount B. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica’s Board of Directors participated in the financing Proceeds expected to strengthen the Company's balance sheet and fund opera...

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into a Master Services Agreement (MSA) with a confidential life sciences company to develop proprie...

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-gu...

The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual, claim-by-claim basis under Medicare’s standard claims approval process. The ...

— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy  — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally — Up to Five Million Canadians ...

2026-04-14 01:44:23 ET More on Biomerica Financial information for Biomerica Read the full article on Seeking Alpha For further details see: Biomerica reports Q3 results

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended Febru...

2026-03-18 08:47:08 ET More on Biomerica Financial information for Biomerica Read the full article on Seeking Alpha For further details see: Biomerica gets first commercial order for H. pylori test

First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe. Strategic Account: This new lab’s scale and geographic reach across Europe positions it as a r...